Related Experiment Video
Updated: Jul 23, 2025

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report
K D Tiver1,2, D K Martin3, J Quah1,2
1Department of Cardiology, Flinders Medical Centre, Level 6, Flinders Drive, Bedford Park, SA, 5042, Australia.
Insights
Diltiazem failed to prevent dangerous 1:1 atrial flutter in a patient taking flecainide. This highlights potential risks when combining these anti-arrhythmic drugs for atrial fibrillation management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial flutter with 1:1 ventricular conduction is a critical arrhythmia.
- Current guidelines suggest combining AV nodal blockers with Class 1C anti-arrhythmics for prophylaxis.
- Guidance on AV nodal blockade type and dosage is lacking, leading to suboptimal use.
Observation:
- A 62-year-old male patient with atrial fibrillation on flecainide presented with 1:1 atrial flutter.
- Cardioversion was performed, and diltiazem was added for prophylaxis.
- The patient recurred with 1:1 atrial flutter despite diltiazem prophylaxis.
Findings:
- Diltiazem failed to prevent 1:1 atrial flutter in a patient on chronic flecainide therapy.
- This case illustrates a potential drug interaction or inadequate blockade.
Implications:
- Clinicians should be aware of the potential for diltiazem to fail in preventing 1:1 flutter when used with flecainide.
- Further research is needed to clarify optimal prophylactic strategies for 1:1 atrial flutter in patients on Class 1C agents.
- This case underscores the importance of individualized treatment approaches in managing complex cardiac arrhythmias.
Background:
Atrial flutter with 1:1 conduction to the ventricles is a dangerous cardiac arrhythmia. Contemporary guidelines recommend atrioventricular nodal blocking agents should be co-administered with class 1C anti-arrhythmics, as prophylaxis against 1:1 flutter. No guidance is provided on the type or strength of atrioventricular nodal blockade required, and in practice, these agents are frequently prescribed at low dose, or even omitted, due to their side effect profile.
Case Presentation:
A 62 year old Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted. Diltiazem was added to prevent this complication and he again presented with atrial flutter with 1:1 conduction to the ventricles, despite prophylaxis with coadministration of diltiazem.
Conclusions:
This case report demonstrates failure of diltiazem to prevent 1:1 flutter in a patient chronically treated with flecainide for paroxysmal atrial fibrillation.
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias

